Clinical Trials Browser

Phase 2/3 × INDIV × Myasthenia Gravis × Clear all

NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Phase 2/3 Not yet recruiting

Myasthenia Gravis